The efficacy of the combination of pyrimethamine and sulfadiazine for the treatment of congenital Toxo plasma gondii infection in rhesus monkeys was studied. The dosage regimen for pyrimethamine and sulfadi azine was established by pharmacokinetic studies in two monkeys. Those studies showed that the distributions of both drugs followed a one-compartment model. The serum elimination half-lives were found to be 5.2 h for sulfadiazine and 44.4 h for pyrimethamine. Sulfadiazine reached a maximum concentration in serum of 58.7 |xg/ml, whereas a maximum concentration in serum of 0.22 fxg/ml was found for pyrimethamine. Ten monkeys were infected intravenously with T. gondii at day 90 of pregnancy, which is comparable to the second trimester of organogenetic development in humans. Treatment was administered to six monkeys, in whose fetuses infection was diagnosed antenatally. From the moment that fetal infection was proven, the monkeys were treated throughout pregnancy with 1 mg of pyrimethamine per kg of body weight per day and 50 mg of sulfadiazine per kg of body weight per day orally, The therapy was supplemented with 3.5 mg of folinic acid once a week. No toxic side effects were found with this drug regimen. The parasite was no longer detectable in the next consecutive amniotic fluid sample, taken 10 to 13 days after treatment was started. Furthermore, T. gondii was also not found in the neonate at birth. The parasite was still present at birth in three of four untreated fetuses that served as controls. Both drugs crossed the placenta very well. Concentrations in fetal serum varied from 0.05 to 0.14 |xg/ml for pyrimethamine and from 1.0 to 5.4 |xg/ml for sulfadiazine. In addition, pyrimethamine was found to accumulate in the brain tissue, with concentrations being three to four times higher than the corresponding concentrations in serum. Thirty percent of the sulfadiazine was found to reach the brain tissue when compared with the corresponding serum drug concentration. When administered early after the onset of infection, the combination of pyrimethamine and sulfadiazine was clearly etfective in reducing the number of parasites in the fetus to undetectable levels.
A congenitally acquired Toxoplasma gondii infection is gen erally treated with the combination of pyrimethamine and sul fadiazine (37) . Both components are inhibitors of folate me tabolism, acting synergistically to suppress the proliferation of the parasite by indirect impairment of DNA synthesis (16, 48) .
Several studies in mice revealed that the combination of pyrimethamine and sulfadiazine reduces the parasitic load and prolongs the survival of mice after infection with a lethal dose of T. gondii (14, 31, 32) . Studies on the effectiveness of py rimethamine and sulfadiazine for the treatment of congenital T. gondii infections in humans, however, have been scarce. Those studies that have been reported in the literature are from France (10, 11, 20) . Those tiveness of treatment with pyrimethamine and sulfadiazine af ter fetal infection had been proven. The studies revealed that in utero treatment significantly reduced the number of infected offspring with severe toxoplasmosis. In addition, a relative de crease in benign to subclinical forms of infection was found. However, several of the offspring were still found to have intracranial calcifications or retinal scars which developed into chorioretinitis (10, 11, 20) . It is not known whether these find ings were due to the fact that the onset of treatment was concentra- amine and ; in s were too pyr low to be effective.
On the other hand, the effects described by (10, 11, 20) cannot solely be attributed to py rimethamine and sulfadiazine, since all patients treated with spiramycin throughout pregnancy, from the mo ment that maternal infection was diagnosed or suspected. An effect of the antibiotic cannot be ignored. A former study in the rhesus monkey showed that spiramycin reduces the parasitic load to undetectable levels in congenitally infected fetuses (40) . Therefore, some of the effects in the French studies may have In caused by spiramycin, present study, the efficacy of pyrimethamme-sulfadi i n started early after the onset of fetal infection.
of the pharmacokinetics of these drugs were performed in this animal species tion of the dosaae regimen. Although extensive studies have armac in a of animals, little is known about keys. The disposition of sulfadiazine has s mon m of 0.5 to 1.5 years of age (29, However, results obtained in immature monkeys may be of limited relevance to adult monkeys, as has been found in pigs
The kinetics of sulfadiazine in adult monkeys have not reported. The pharmacological studies of pyrimethamine in rhesus monkeys by Schmidt et al. (38) focused mainly on tissue localization, A n t im ic r o b . A g e n t s C i-ie m o t h e r .
In the present study the kinetic parameters of py rimethamine and sulfadiazine were determined in adult mon keys receiving a drug regimen that is applied to humans for the treatment of congenital T. gondii infections. Following this, transplacental transfer and the distributions of the drugs in tissue were investigated in pregnant monkeys. The effects of the treatment are related to the concentrations of py rimethamine and sulfadiazine that are reached in the fetus. 
MATERIALS AND METHODS
Monkeys. All monkeys were derived from the Laboratory Animals Breeding Experimental Farm of Shunde Guangdong, Beijing, People's Republic of China, Breeding of the monkeys and animal care have been described before (43) .
The treatment group consisted of 10 female monkeys (monkeys D1 to DIO) that were seronegative for antibodies to 71 gondii before the experiments were started. A group of four untreated monkeys (monkeys A 6 to A9), in whose fetuses infection had been proven, served as controls. This control group has been described in detail before (41). The purpose of the former study was to investigate whether the rhesus monkey was a suitable animal for use in the study of congenital 7! gondii infections (41). In addition, we meant to use this group of monkeys as untreated controls. The outcome of fetal infection in the control group is summarized in this report. The fetuses and babies of the monkeys are indicated by D fl to D fl() for the treatment group and A (6 to A f9 for the control group.
The pharmacokinetics of pyrimethamine and sulfadiazine were studied in two nonpregnant monkeys (monkeys E and F) after oral administration of a single dose of 1 mg of pyrimethamine per kg of body weight in combination with 50 mg of sulfadiazine per kg of body weight.
Pharmacokinetic studies with two nonpregnant monkeys. Tablets of py rimethamine (Daraprim) were obtained from Wellcome Pharmaceuticals, Utrecht, The Netherlands, and capsules containing sulfadiazine were provided by the Department of Clinical Pharmacy of the University Hospital Nijmegen. Sulfadiazine was obtained from the Onderlinge Pharmaceutische Groothandel (Utrecht, The Netherlands).
The pharmacokinetics of pyrimethamine and sulfadiazine were studied in nonpregnant monkeys E and F after oral administration of 1 mg of pyrimethamine per kg in combination with 50 mg of sulfadiazine per kg. These dosages were chosen because they are normally used to treat congenital 71 gondii infections in humans (27, 34, 37) .
Pulverized pyrimethamine and sulfadiazine were hidden in a small hole within a LIGA biscuit (General Biscuits Nederland BV, Rozendaal, The Netherlands) covered with marmeladc or in a small piece of banana, and the monkeys were given the food.
Blood samples of 5 ml were collected from the vena mediana just before and at 1, 2, 3, 4, 5, 6, 7, 8, 10, 12, 24, 48, 72, and 96 h after drug administration, The blood samples were centrifuged at 800 X g for 10 min. The sera were collected and stored at -20°C until analysis.
Experimental design and collection of clinical samples. A time schedule of sample collection is shown in Fig. 1A . A 71 gondii infection was induced in the monkeys at day 90 of pregnancy. The time point of infection is comparable to the second trimester of organogenetie development in humans, The infection was induced by intravenous inoculation of 5 X 10h tachyzoites of 71 gondii (RH strain). Maternal parasitemia was tested for 8 days after inoculation of the monkeys, at amniotic punctures, and at the time of delivery by cesarean section as described before. In brief, all clinical samples (blood, amniotic fluid, placenta, and fetal tissues) were tested for the presence of 71 gondii by inoculation of mice (44) and by nested PCR (39, 41) , Fetal infection in the control group was tested 10 days after inoculation of the mother by examination of fetal blood and amniotic fluid. The transmission of infection was examined again at birth by testing the amniotic fluid and the blood and tissues of the neonates (Fig. IB) (41) .
To monitor the effect of treatment during pregnancy, two additional samples obtained by amniotic puncture were included in the protocol for the treatment group. Amniotic fluid samples were thus obtained at 10, 25, and 40 days after inoculation of the mother (Fig, 1C) . A cesarean section was performed at day 160 of pregnancy, which was about 10 days before the expected date of delivery. Amniotic fluid, placental tissue, and neonatal blood from the umbilical cord were collected and tested for the presence of 71 gondii. The mothers and neonates were sacrificed, and autopsies were performed. The heart, brain, spleen, liver, and lungs were examined for the presence of 71 gondii Processing of clinical samples. The protocols for the processing of the clinical samples have been described in detail previously (40, 41, 44) . In brief, 6 ml of amniotic fluid was collected at each amniotic puncture. Two mice were each inoculated intraperitoneally with 1 ml of amniotic fluid to test for the presence of 71 gondii The remaining 4 ml was divided into portions of 1 ml each, and each portion was centrifuged at 800 x g for 10 min. The sediments of each portion were resuspended in 100 |Jil of physiological salt solution. DNA was isolated from two portions with guanidinium thiocyanate and silica particles exactly as de scribed by Boom et al. (6). The remaining two portions were stored at -80°C. (A) Time schedule of sample collection during pregnancy. I, infec tion, 90 days after conception; C, collection of maternal blood for control of parasitemia; AP, amniotic puncture; FBS, fetal blood sampling; CS, delivery by cesarean section. During fetal blood sampling both amniotic fluid and fetal blood were collected. During delivery by cesarean section amniotic fluid, neonatal blood, and the placenta were collected. Delivery by cesarean section was fol lowed by autopsy of the neonate, and the heart, spleen, brain, and liver were obtained. All samples were tested for the presence of 71 gondii. (B) Results for the four monkeys in the control group that received no treatment. The detection of 71 gondii in the amniotic fluid and/or neonatal tissues is indicated with a plus sign, A premature birth is indicated by an arrow and the duration of pregnancy. + *, fetal infection proven by the demonstration of antibodies in the neonate at serological follow-up. (C) Results for the six monkeys in the study group that were treated with pyrimethamine-sulfadiazine. The detection of 71 gondii in the amniotic fluid is indicated with a plus sign. The days at which treatment with pyrimethamine-sulfadiazine was started are marked with arrows.
The placenta and neonatal organs were homogenized in physiological salt solution as described before (40) . Each sample was tested in duplicate for the presence of parasites by inoculation into mice. DNA was isolated from the tissues by incubation in 6% /^aminosalicylic acid-1 % NaCl-10 mM EDTA with 0.5 jig of proteinase K per ml at 37W C for 3 h. A fter phenol extraction, the DNA was precipitated overnight at -20°C. One microgram of the tissue DNA was tested for the presence of 71 gondii by a nested PCR on the ribosomal DNA gene as described before (39, 41) .
Treatment with pyrimethamine and sulfadia2ine. Treatment with py rimethamine and sulfadiazine was started as soon as congenital infection was proven by detection of the parasite in the amniotic fluid and was continued until the mother gave birth. Transmission of infection occurred in 6 of the 10 monkeys of the treatment group (monkeys D2, D3, D 6, D7, D9, and DIO). The efficacy of pyrimethamine-sulfadiazine was studied in these six monkeys. The monkeys were treated orally with 1 mg of pyrimethamine per kg/day and 50 mg of sulfadiazine per kg/day. The drugs were administered as described above in the section on pharmacokinetic studies, In addition, folinic acid (3.5 mg) was administered orally once a week in order to counteract the bone marrow suppression caused by pyrimethamine (37) . The cookies and bananas containing the drugs were always eaten eagerly, and the complete dose was consumed. Two monkeys, D3 and D9, refused the dose once. ,PC)., (85%; wt/wt) and 0.6 g of telrarnethylammonkimehloride in 1 liter of water mixed with 1 liter of acetonitrile (vol/vol) and was run at a flow rate of 1.5 ml/min. UV detection was achieved at 220 nm. The quantitation limit of pyrimethamine was 0.05 p-g/ml at a signal-to-noi.se ratio of 3. The pure pyrimethamine that was used as a reference in HPLC was kindly provided by The Wellcome Foundation (Kent, England).
Sulfadiazine was measured by gradient HPLC analysis. The HPLC system consisted of a Dynamax 6.0-nm C8 column (particle size, 8 fxm; 4.6 by 250 mm [inner diameter); Raimn Instruments Co. Inc., Woburn, Mass.). At time zero, the eluent consisted of 10% acetonitrile and 90% of a Wo acetic acid solution in water. In 18 min the eluent changed linearly to 28% acetonitrile and 72% acetic acid (1%). The flow rate for the solvent was 1.5 ml/min, and detection was achieved at 272 nm. The detection limit of sulfadiazine was 0.2 ng/ml at a signal-to-noise ratio of 3.
The intraday and interday coefficients of variation were calculated for serum samples. The coefficients were found to be 6.4 and 7.7%, respectively, for py rimethamine and 3.2 and 1.9%, respectively, for sulfadiazine.
Curve fitting (r2 > 0.97) and estimation of pharmacokinetic parameters were done with the aid of the computer programm MW/PHARM (33).
Statistical evaluation. Fisher's exact test for the comparison of proportions was used to compare the probabilities of infection in the treatment and control groups. Furthermore, 80 and 95% confidence intervals were calculated for an infection-free outcome of therapy. The confidence intervals were based on a binomial distribution (5).
RESULTS
Pharmacokinetic studies. The pharmacokinetics of py rimethamine and sulfadiazine were determined after oral ad- lives were found to be 44.4 h for pyrimethamine and 5.2 h for sulfadiazine. A maximum concentration in serum, of 58.7 |xg of sulfadiazine per ml was reached at 3.7 h after administration. At 2.7 h after administration of 1 mg of pyrimethamine per kg a peak concentration of 0.22 (xg/ml in serum was found.
Treatment of congenital T. gondii infections. The 4 monkeys in the control group and the 10 monkeys in the treatment group all developed a parasitemia that lasted for about 10 days. Parasitemia was demonstrated by the isolation of parasites from maternal blood by both mouse inoculation and detection by PCR.
As described in detail in our previous report (41), T. gondii was detected in four of the nine fetuses of the control group (Af6 to Af9). The results are summarized in Figure IB .
Fetal infection in the treatment group was monitored prenatally by sequential testing of amniotic fluid samples obtained by puncture at days 100,115, and 130 of pregnancy. Transmisministration of 1 mg of pyrimethamine per kg with 50 mg of sion of infection was found in 6 of the 10 monkeys (Df2, Df3, sulfadiazine per kg to nonpregnant monkeys E and F. The Df6, Df7, Df9, and Df10). The parasite was detected by PCR in concentrations of pyrimethamine and sulfadiazine in serum are the amniotic fluid of all six monkeys, whereas mouse inoculapresented in the Fig. 2 and 3, respectively. tion was positive only for monkeys Df2, Df9, and Df10. In four T serum concentration-time curves of both pyrimeof six monkeys, the transmission of infection occurred within thamine and sulfadiazine fit best to a one-compartment model 10 days after inoculation of the mother, in monkey D7 between Flie pharmacokinetic parameters that were calculated from days 10 and 25, and in monkey D10 between days 25 and 40 these data are shown in Table 1 . The serum elimination half- (Fig. 1C ).
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2 ) As shown in Fig. 1C , treatment was started in the six mon keys shortly after collection of the amniotic fluid samples and infection was proven. In four monkeys (monkeys D2, D3, D6, and D9) the time interval between collection of the amniotic than the concentrations in serum. Both pyrimethamine and amniotic fluid sample from any monkey collected 10 to 13 days after the initiation of treatment ( Figure 1C) . Postnatally, the parasite was not found in neonatal tissues or amniotic fluids. The placenta of monkey DIO, which received treatment for 25 days, was the only sample found to be positive at birth. The placenta was found to be positive by PCR but not by mouse inoculation. No hematological side effects from the administered drug regimen were found.
Statistical evaluation of these results revealed that the infec tion rate in the treatment group was similar to the rate in the control group (P = 0.66). Furthermore, the outcome of fetal infection after treatment was significantly different from the outcome in the control group (P = 0.033). The confidence intervals were calculated for this small number of animals; the 80% confidence limits were 0 to 28%, whereas the 95% con fidence limits were 0 to 40%. The drug concentrations at which these effects occurred are given in Tables 2 and 3 . The time interval between the last dose and the collection of samples was 4 h for monkeys D3 and D10 (peak levels) and about 26 h for monkeys D2, D6, D7, and D9 (trough levels). The concen trations in fetal serum varied from 0.05 to 0.14 |xg/ml for pyrimethamine and from 0.6 to 5.4 (ig/ml for sulfadiazine. Pyrimethamine was found to accumulate in the soft tissues, especially in the spleen and the lungs. Sulfadiazine was also found in the tissues, but the concentrations were always less fluid sample and the initiation of treatment was only 2 days. The parasite was no longer detectable in the next consecutive sulfadiazine crossed the placenta of the rhesus monkey very well, as shown in Table 4 . Pyrimethamine penetrated into brain a The day of sample collection corresponds to pregnancy duration, h The average time interval between the last d o sin g and sample collection was 26 h. Thus, the concentrations in serum presented here are mainly trough levels. For monkeys D3 and DIO at day 160 of pregnancy, th e time interval was 4 h, c NT, no treatment at that moment. c/ The concentrations in tissue were determ ined by using tissue extracts which were diluted five times in physiological salt solution. If a concentration in tissue was found to be < 0.2 fxg/rnl, this means that this was th e concentration in the diluted sample.
c? NA, sample not available.
.55* than the rimethamine in the brain were about greater than the corres aliens py-the growth of the parasite in vitro (12, 24, 42) . The inhibition of growth was associated with a reduction in the number of s in s whereas the concentrations of sulfadiazine were to and the number of intracellular parasites (12, 24) . Pyrimethamine and sulfadiazine also cause morphological about 30% of the corresponding concentrations in serum (Tachanges in the parasite, as demonstrated by electron microsble 4). copy (42) .
DISCUSSION
in mice have shown that treatment with py rimethamine and sulfadiazine prolongs survival after infection with a lethal dose of T. gondii by reducing the parasite load (14, and Stadtsbaeder (31) found that mice treated
The antitoxoplasma activities of pyrimethamine and sulfadi azine have been demonstrated both in vitro and in vivo. Py rimethamine and sulfadiazine act synergistically on T. gondii, with pyrimethamine and sulfadiazine acquired no resistence to and it appeared that the combination of these drugs inhibits a lethal challenge with T. gondii. Treatment with pyrimethamine h Transplacental passage is expressed as the ra tio between the concentration of the drug in fetal serum and the corresponding concentration in maternal serum. The ratio between the concentration in the brain and th e corresponding concentration in serum gives an impression of the level of penetration of the drug into the brain. * * The day of sample collection corresponds to pregnancy duration. d ND, not determined because the drug concentration was below the detection level or because there was no treatment given at that moment.
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in pigs, who found that the half-life of sulfadiazine decreased Studies in humans revealed that treatment with pywith an increase in the ages of the pigs. rimethamine and sulfadiazine significantly reduced the number
The pyrimethamine half-life of 44.4 h found in rhesus monof offspring with severe congenital toxoplasmosis (9) (10) (11) 20) .
keys is shorter than the 85 to 114 h reported in humans (8, 26) . Several children, however, were born suffering from subclinical When compared with those in babies, however, the half-life in or even symptomatic toxoplasmosis, despite treatment with serum was only slightly shorter than the reported 64 ± 12 h pyrimethamine and sulfadiazine (7, 10, 11, 20) . The treatment (28). On the basis of the serum half-life of pyrimethamine of these children was started after fetal infection had been observed in the rhesus monkey, a frequency of one dose every proven. The prenatal diagnosis of infection was time-consum-' 1 or 2 days would be appropriate. Because the half-life of ing most of the time, and the studies contained no information sulfadiazine is 5.2 h, however, a more frequent dosing would be about the duration of infection at the moment that therapy was required. started. The time interval between the onset of fetal infection
The pharmacokinetic studies were performed with nonpregand the initiation of therapy was therefore possibly too long. In nant monkeys. Given the effects of pregnancy on the volume of the present study the moment of infection was adequately distribution and renal blood flow, drug clearance could be known. Because antenatal detection of T. gondii was perdifferent. Further investigation of these parameters needs to be formed by PCR, a result can be obtained within 2 days of performed to establish the dosages of the drugs in the treatreceiving the sample, and treatment could be started early after the onset of fetal infection in our experimental setup. By PCR, transmission of infection was detected antenatally in six monkeys, whereas mouse inoculation was positive for only three monkeys. The high degrees of sensitivity and reproduc ibility of the PCR were also found in our former study (40) . It has been stated before that PCR cannot discriminate between viable and dead parasites. However, since transmission of dead ment of humans.
Weiss et al. (47) demonstrated that the concentration of pyrimethamine in the sera of mice should be at least 0.5 |xg/ml to be effective in inhibiting Toxoplasma growth. When py rimethamine was used in combination with sulfadiazine, the |xg/ml (jug/ml tions that were found to be effective in vivo were in close parasites is unlikely, the detection of T. gondii in amniotic fluid agreement with those that were found to be effective in vitro by PCR is considered to be of clinical importance. (24, 42) . Lower concentrations of 0.02 |xg of pyrimethamine Statistical analysis of the results revealed that the rate of per ml in combination with 0.1 |xg of sulfadiazine per ml, transmission of infection to the fetuses in the control group however, also had an inhibitory effect (12) . Such concentrawas similar to the rate in the treatment group. In addition, tions were easily reached in the rhesus monkeys by the investreatment with pyrimethamine and sulfadiazine significantly tigated dose regimen. Concentrations of 5:25 |xg of sulfadiareduced the number of infected offspring compared with the zine per ml were present in the sera of adult monkeys for about number of infected untreated controls.
10 h, and concentrations of ^0.1 |xg of pyrimethamine per ml The efficacy of treatment was related to the concentrations were present in sera for more than 24 h after single oral dosing, of the drugs that were reached in the fetus. Both pyGiven the high rate of transplacental passage of both drugs, it rimethamine and sulfadiazine can cross the placenta freely and is assumed that such effective concentrations in serum are also are therefore thought to be appropriate drugs for use in the present in the fetus. On the basis of these findings a single dose treatment of congenital T. gondii infection (13) . The concenpyrimethamine given every day would be appropriate. The trations of pyrimethamine in the sera of neonates varied from half-life of sulfadiazine of 5.2 h and the time during which 38 to 81% of the corresponding concentrations in the sera of effective concentrations are present in serum, however, would the mothers. The concentrations of sulfadiazine in the sera of the fetuses were similar to those in the sera of the mothers. The same results have also been found for transplacental pas sage of pyrimethamine and sulfadoxine in humans (13) . This require two doses per day. For practical reasons py rimethamine and sulfadiazine were administered together in a single dose.
Concentrations of 0.1 to 0.5 |xg of pyrimethamine per g were was expected because rhesus monkeys and humans both posalso reached in the tissues of the rhesus monkey. Because in sess a placenta of the hemochorial type (35) . Since brain dammost cases trough levels were measured, concentrations in age is the most severe consequence of congenital toxoplasmo-H-g/ml sis, the concentrations in the brain are of special interest. It was two monkeys (monkeys D3 and DIO), the levels in serum were found that pyrimethamine and sulfadiazine both can cross the measured approximately 4 h after administration of the last blood-brain barrier in the rhesus monkey. The concentrations dose. In these cases concentrations in serum greater than 0.1 of sulfadiazine in the brain were found to be about 35% of the |xg/ml concomitant concentrations in serum for both the fetus and the tered drug regimen were found in the rhesus monkeys. Pymother. These percentages are in close agreement with the rimethamine, however, should not be given in excess of doslevels of sulfadiazine that have been found in the cerebrospinal of 1.25 mg/kg/day since higher cannot be fluid of dogs (45) and humans (46) . Pyrimethamine was found tolerated by rhesus monkeys when they are administered reto penetrate and accumulate in monkey brain tissue, and conpeatedly (38) . It should be mentioned, however, that in the centrations up to 4.5 times the concomitant levels in serum study of Schmidt et al. (38) the treatment was not supplewere found. This was already expected from experiments in mented with folinic acid, as was the case in the present study.
humans (23), rhesus monkeys (38) , and rats (8), in which sim ilar ratios of levels in brain to levels in serum were found.
At high doses pyrimethamine has been found to have terat ogenic effects in rats (19, 21, 43) and miniature pigs (18) . Pharmacokinetic studies revealed that pyrimethamine and Besides this, sulfadiazine should not be administered during sulfadiazine have serum half-lives of 44.4 and 5.2 h, respecthe last month of pregnancy because it increases the risk of lively, in the rhesus monkey. Sulfadiazine has a shorter elimikernicterus (48) . Kernicterus was not investigated in the monnation half-life in rhesus monkeys than in humans (1, 25, 36). In addition, the elimination half-life found in adult monkeys in the present study is shorter than that reported for young mon keys used in the present study, which were killed immediately after birth.
The risk of teratogenic effects caused by pyrimethamine and the risk of kernicterus caused by sulfadiazine create a reluctance to use this drug cornbination for the prevention of trans mission of infection. Therefore, the safer antibiotic spiramycin is given as long as fetal infection has not been proven. A former study in rhesus monkeys showed that spiramycin is able to reduce the number of parasites in amniotic fluid to unde tectable levels (40) . However, spiramycin had to be adminisiired for at least 3 weeks to be effective (40) . Treatment with ..... , • mc| suifac]iazjn0i on otiier hand, showed same effect within 10 to 13 days.
of malformations, the use of py rimethamine and sulfadiazine during pregnancy has been disshed work, however, revealed no grounds for contraindication during pregnancy (2) . On the basis of these findings, the drug combination instead of spiramycin should be used to prevent the transmission of infection because of the potent activity of the combination against T. gondii parasites. last month of pregnancy (i.e., after 36 weeks or arlier if an anamnesis exists for premature birth) sulfadiazine out because of the risk of kernicterus. It appears from the results of the present study that the combination of pyrimethamine and sulfadiazine is an effective drug regimen for the treatment of congenital T. gondii infec tion. Pyrimethamine and sulfadiazine act on the proliferative stage of the parasite but not on cysts in tissues. The eradication of cysts is very important because of the risk of developing chorioretinitis later in life (22) . Studies should focus on new drugs that cross the blood-brain barrier and that act on the cysts as well. Initial studies with atovaquone showed promising 4). On long-term probation, however, atovaquone was not able to eradicate the cysts from infected mouse brains
In conclusion, when administered early after the onset of fetal infection the combination of pyrimethamine and sulfadi azine is an effective drug regimen for the treatment of congen ital T. gondii infections.
